AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Idiopathic Inflammatory Myopathy (IIM)

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597Phase 12 sites๐Ÿ“ Beijing๐Ÿ“ Beijing Beijing GoBroad Hospital ยท Tests: OL-108 A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies NCT06698796Phase 326 sites๐Ÿ“ Glendale๐Ÿ“ Frisco๐Ÿ“ Houston Pfizer ยท Tests: Dazukibart A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases NCT07284797Phase 11 site๐Ÿ“ Melbourne Xencor, Inc. ยท Tests: XmAb657 Adult Autoimmune Myopathies (MAIA) NCT04792931NA1 site๐Ÿ“ Brest University Hospital, Brest ยท Tests: description of adult autoimmune myopathies Adult and Juvenile Myositis NCT00017914n/a4 sites๐Ÿ“ Atlanta๐Ÿ“ Bethesda๐Ÿ“ Research Triangle Park National Institute of Environmental Health Sciences (NIEHS) Safety Study of CC312 in Autoimmune Disease Patients NCT06888960EARLY Phase 11 site๐Ÿ“ Tianjin CytoCares Inc ยท Tests: CC312 A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease NCT07085104Phase 117 sites๐Ÿ“ Phoenix๐Ÿ“ Loma Linda๐Ÿ“ Aurora Allogene Therapeutics ยท Tests: ALLO-329, Cyclophosphamide, Fludarabine Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis NCT06479863EARLY Phase 12 sites๐Ÿ“ Austin๐Ÿ“ Austin Austin Neuromuscular Center ยท Tests: Pozelimab/Cemdisiran Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases NCT06285539Phase 26 sites๐Ÿ“ Amsterdam๐Ÿ“ Heerlen๐Ÿ“ Nijmegen UMC Utrecht ยท Tests: Filgotinib Optimizing Treatment on Idiopathic Inflammatory Myopathies NCT03092180n/a1 site๐Ÿ“ Sรฃo Paulo University of Sao Paulo ยท Tests: Intravenous Infusion FT839 in Autoimmune Diseases NCT07800871Phase 1, Phase 21 site๐Ÿ“ Fullerton Fate Therapeutics ยท Tests: FT839 RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy NCT06154252Phase 2, Phase 338 sites๐Ÿ“ Orange๐Ÿ“ San Francisco๐Ÿ“ Aurora Cabaletta Bio ยท Tests: CABA-201 following preconditioning with fludarabine and cyclophosphamide An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases NCT07174843EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Cell Therapy Group Co.,Ltd ยท Tests: CD19/CD22/BCMA CAR-T cells(BZE2204) Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy NCT07103746Phase 28 sites๐Ÿ“ Birmingham๐Ÿ“ Atlanta๐Ÿ“ Chicago National Institute of Allergy and Infectious Diseases (NIAIโ€ฆ ยท Tests: Ublituximab, Placebo for Ublituximab Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases NCT07085676Phase 11 site๐Ÿ“ Jerusalem Polina Stepensky ยท Tests: HBI0101 CART Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases NCT06548607EARLY Phase 11 site๐Ÿ“ Bengbu Nanjing Bioheng Biotech Co., Ltd. ยท Tests: CD19 or CD19-BCMA CAR-T GC012F Injection in Refractory Idiopathic Inflammatory Myopathy NCT07086404EARLY Phase 11 site๐Ÿ“ Wuhan Daishi Tian ยท Tests: GC012F Injection infusion AYLo - AutoimmunitY and Loss of y NCT06696027n/a1 site๐Ÿ“ Bonn University of Bonn ยท Tests: Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplexโ€ฆ Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases NCT06614270NA1 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Anti-CD19 IL-10/IL15 CAR-NK Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy NCT07150000n/a1 site๐Ÿ“ Bonn University of Bonn ยท Tests: Ex Vivo Assay Biomarkers in Autoimmune Disease of Nervous System NCT06502015n/a1 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: biomaker levels Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases NCT07087912Phase 42 sites๐Ÿ“ Sรฃo Paulo๐Ÿ“ Sรฃo Paulo University of Sao Paulo General Hospital ยท Tests: Dengue 1,2,3,4 (attenuated) vaccine EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases NCT07077304n/a1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris ยท Tests: observational study Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197Phase 1, Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University General Hospital ยท Tests: BAFF-R CART A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) NCT07331272Phase 15 sites๐Ÿ“ Bengbu๐Ÿ“ Guangzhou๐Ÿ“ Changsha Nanjing Legend Biotech Co. ยท Tests: LUCAR-G79D T cells Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. NCT07526493Phase 11 site๐Ÿ“ Wuhan Tongji Hospital ยท Tests: Universal CD19 CAR-ฮณฮดT Cell Injection, Cyclophosphamide, Fludarabine CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases NCT07315087Phase 11 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: QT-019C OM336 in Seropositive Autoimmune Diseases NCT07229144Phase 11 site๐Ÿ“ Hamilton Lakefront Biotherapeutics West LLC ยท Tests: OM336 A Study of AZD0120 in Autoimmune Diseases NCT07295847Phase 122 sites๐Ÿ“ Tucson๐Ÿ“ Stanford๐Ÿ“ Chicago AstraZeneca ยท Tests: AZD0120 A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] NCT05895786Phase 3138 sites๐Ÿ“ Glendale๐Ÿ“ Phoenix๐Ÿ“ Phoenix Pfizer ยท Tests: PF-06823859, Placebo
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy